Lupus clinical trials and the promise of future therapies.

Abstract

E-mail: ada20@cumc.columbia.edu; https://orcid.org/0000-0003-4597-5023 Several successful phase 3 trials and the approval of these new therapies in systemic lupus erythematosus (SLE), have resulted in increased interest in drug development in lupus.[1-3] Despite the recent approval of new therapies for SLE and lupus nephritis (LN) there is still an urgent need for advanced therapies as response rates are still in the 50%–60% range.[4–6]